Lower dose pembrolizumab with chemo for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have cervical cancer that has spread, come back, or cannot be surgically removed, and your tumor has a PD-L1 CPS score of 1 or higher.
- You have not had chemotherapy for advanced cervical cancer before (chemotherapy given with radiation is allowed if finished at least 2 weeks ago and side effects have resolved).
- You have a tumor that can be measured by scans (CT or MRI), and it has not been treated with radiation unless it has grown since then.
- You are willing to provide a tumor tissue sample (from a biopsy or an archived sample no more than 4 years old) to confirm PD-L1 status.
- You have good overall health (ECOG score 0 or 1) and normal blood counts and organ function as confirmed by recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests GLS-010 added to standard platinum chemotherapy, with or without bevacizumab, as a first treatment for cervical cancer that has persisted, come back, or spread. If you have PD-L1–positive tumors, the goal is to improve how long people can control the cancer compared with standard chemotherapy alone.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Hear when a new Persistent, Recurrent, or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.